ADAMTS13 and von Willebrand factor interactions

Current Opinion in Hematology

Volumn 22, Issue 5, 2015, Pages 452-459

  Zander, Catherine B ^a   Cao, Wenjing ^a   Zheng, X Long ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

ADAMTS13; Autoantibody; Protein protein interaction; Thrombosis; Thrombotic thrombocytopenic purpura; Von willebrand factor

Indexed keywords

ADAMTS 13 ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR ANTIBODY; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; AUTOANTIBODY; EPITOPE;

ANTIBODY SPECIFICITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; STRUCTURE ACTIVITY RELATION; CHEMISTRY; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; PROTEIN DEGRADATION; PROTEIN TERTIARY STRUCTURE; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

ADAM PROTEINS; ADAMTS13 PROTEIN; ANTIBODY SPECIFICITY; AUTOANTIBODIES; HUMANS; IMMUNODOMINANT EPITOPES; PROTEIN STRUCTURE, TERTIARY; PROTEOLYSIS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; STRUCTURE-ACTIVITY RELATIONSHIP; VON WILLEBRAND FACTOR;

EID: 84942811733     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0000000000000169     Document Type: Review

References (98)

1. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-494.
2. Zheng X, Chung D, Takayama TK, et al. Structure of von Willebrand factorcleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001; 276: 41059-41063.
3. Fujikawa K, Suzuki H, McMullen B, et al. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001; 98: 1662-1666.
4. Uemura M, Tatsumi K, Matsumoto M, et al. Localization of ADAMTS13 to the stellate cells of human liver. Blood 2005; 106: 922-924.
5. Zhou W, Inada M, Lee TP, et al. ADAMTS13 is expressed in hepatic stellate cells. Lab Invest 2005; 85: 780-788.
6. Niiya M, Uemura M, Zheng XW, et al. Increased ADAMTS-13 proteolytic activity in rat hepatic stellate cells upon activation in vitro and in vivo. J Thromb Haemost 2006; 4: 1063-1070.
7. Soejima K, Mimura N, Hirashima M, et al. A novel human metalloprotease synthesized in the liver and secreted into the blood: Possibly, the von Willebrand factor-cleaving protease? J Biochem 2001; 130: 475-480.
8. Turner N, Nolasco L, Tao Z, et al. Human endothelial cells synthesize and release ADAMTS-13. J Thromb Haemost 2006; 4: 1396-1404.
9. Shang D, Zheng XW, Niiya M, et al. Apical sorting of ADAMTS13 in vascular endothelial cells and Madin-Darby canine kidney cells depends on the CUB domains and their association with lipid rafts. Blood 2006; 108: 2207-2215.
10. Liu L, Choi H, Bernardo A, et al. Platelet-derived VWF-cleaving metalloprotease ADAMTS-13. J Thromb Haemost 2005; 3: 2536-2544.
11. Suzuki M, Murata M, Matsubara Y, et al. Detection of von Willebrand factorcleaving protease (ADAMTS-13) in human platelets. Biochem Biophys Res Commun 2004; 313: 212-216.
12. Feys HB, Liu F, Dong N, et al. ADAMTS-13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences. J Thromb Haemost 2006; 4: 955-962.
13. Rieger M, Ferrari S, Kremer Hovinga JA, et al. Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA). Thromb Haemost 2006; 95: 212-220.
14. Soejima K, Nakamura H, HirashimaM, et al. Analysis on the molecular species and concentration of circulating ADAMTS13 in Blood. J Biochem 2006; 139: 147-154.
15. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998; 67: 395-424.
16. Wagner DD, Marder VJ. Biosynthesis of von Willebrand protein by human endothelial cells: Processing steps and their intracellular localization. J Cell Biol 1984; 99: 2123-2130.
17. Sadler JE. von Willebrand factor. J Biol Chem 1991; 266: 22777-22780.
18. Sporn LA, Chavin SI, Marder VJ, et al. Biosynthesis of von Willebrand protein by human megakaryocytes. J Clin Invest 1985; 76: 1102-1106.
19. Dong JF, Moake JL, Nolasco L, et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002; 100: 4033-4039.
20. Dong JF, Moake JL, Bernardo A, et al. ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor. J Biol Chem 2003; 278: 29633-29639.
21. Dong JF. Cleavage of ultra-large von Willebrand factor by ADAMTS-13 under flow conditions. J Thromb Haemost 2005; 3: 1710-1716.
22. Zheng XL. ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura. Annu Rev Med 2015; 66: 211-225.
23. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-1594.
24. Zheng XL. Structure-function and regulation of ADAMTS-13 protease. J Thromb Haemost 2013; 11 (Suppl 1) : 11-23.
25. Sadler JE. A new name in thrombosis, ADAMTS13. Proc Natl Acad Sci U S A 2002; 99: 11552-11554.
26. Hosler GA, Cusumano AM, Hutchins GM. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases. Arch Pathol Lab Med 2003; 127: 834-839.
27. Tsai HM. Platelet activation and the formation of the platelet plug: Deficiency of ADAMTS13 causes thrombotic thrombocytopenic purpura. Arterioscler Thromb Vasc Biol 2003; 23: 388-396.
28. Tsai HM. ADAMTS13 and microvascular thrombosis. Expert Rev Cardiovasc Ther 2006; 4: 813-825.
29. Kaikita K, Soejima K, Matsukawa M, et al. Reduced von Willebrand factorcleaving protease (ADAMTS13) activity in acute myocardial infarction. J Thromb Haemost 2006; 4: 2490-2493.
30. Matsukawa M, Kaikita K, Soejima K, et al. Serial changes in von Willebrand factor-cleaving protease (ADAMTS13) and prognosis after acute myocardial infarction. Am J Cardiol 2007; 100: 758-763.
31. Andersson HM, Siegerink B, Luken BM, et al. High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women. Blood 2012; 119: 1555-1560.
32. Bongers TN, de Maat MP, van Goor ML, et al. High von Willebrand factor levels increase the risk of first ischemic stroke: Influence of ADAMTS13, inflammation, and genetic variability. Stroke 2006; 37: 2672-2677.
33. Zhao BQ, Chauhan AK, Canault M, et al. von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke. Blood 2009; 114: 3329-3334.
34. Fujioka M, Nakano T, Hayakawa K, et al. ADAMTS13 gene deletion enhances plasma high-mobility group box1 elevation and neuroinflammation in brain ischemia-reperfusion injury. Neurol Sci 2012; 33: 1107-1115.
35. Stepanian A, Cohen-Moatti M, Sanglier T, et al. Von Willebrand factor and ADAMTS13: A candidate couple for preeclampsia pathophysiology. Arterioscler Thromb Vasc Biol 2011; 31: 1703-1709.
36. de Mast Q, Groot E, Asih PB, et al. ADAMTS13 deficiency with elevated levels of ultra-large and active von Willebrand factor in P. falciparum and P. vivax malaria. Am J Trop Med Hyg 2009; 80: 492-498.
37. Larkin D, de Laat B, Jenkins PV, et al. Severe Plasmodium falciparum malaria is associated with circulating ultra-large von Willebrand multimers and ADAMTS13 inhibition. PLoS Pathog 2009; 5: E1000349.
38. Bridges DJ, Bunn J, van Mourik JA, et al. Rapid activation of endothelial cells enables Plasmodium falciparum adhesion to platelet-decorated von Willebrand factor strings. Blood 2010; 115: 1472-1474.
39. Lowenberg EC, Charunwatthana P, Cohen S, et al. Severe malaria is associated with a deficiency of von Willebrand factor cleaving protease, ADAMTS13. Thromb Haemost 2010; 103: 181-187.
40. Kraisin S, Naka I, Patarapotikul J, et al. Association of ADAMTS13 polymorphism with cerebral malaria. Malar J 2011; 10: 366.
41. Kokame K, Matsumoto M, Soejima K, et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factorcleaving protease activity. Proc Natl Acad Sci U S A 2002; 99: 11902-11907.
42. Plaimauer B, Zimmermann K, Volkel D, et al. Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood 2002; 100: 3626-3632.
43. Chung DW, Fujikawa K. Processing of von Willebrand factor by ADAMTS-13. Biochemistry 2002; 41: 11065-11070.
44. Lancellotti S, Basso M, De Cristofaro R. Proteolytic processing of von Willebrand factor by adamts13 and leukocyte proteases. Mediterr J Hematol Infect Dis 2013; 5: E2013058.
45. Barrett AJ, Rawlings ND, Woessner JF. Handbook of proteolytic enzymes. 2nd ed. Amsterdam; Boston: Elsvier Academic Press; 2004.
46. Crawley JT, de Groot R, Xiang Y, et al. Unraveling the scissile bond: How ADAMTS13 recognizes and cleaves von Willebrand factor. Blood 2011; 118: 3212-3221.
47. Apte SS. A disintegrin-like and metalloprotease (reprolysin-Type) with thrombospondin type 1 motif (ADAMTS) superfamily: Functions and mechanisms. J Biol Chem 2009; 284: 31493-31497.
48. Tang BL. ADAMTS: A novel family of extracellular matrix proteases. Int J Biochem Cell Biol 2001; 33: 33-44.
49. Majerus EM, Zheng X, Tuley EA, et al. Cleavage of the ADAMTS13 propeptide is not required for protease activity. J Biol Chem 2003; 278: 46643-46648.
50. Shieh HS, Mathis KJ, Williams JM, et al. High resolution crystal structure of the catalytic domain of ADAMTS-5 (aggrecanase-2). J Biol Chem 2008; 283: 1501-1507.
51. Gerhardt S, Hassall G, Hawtin P, et al. Crystal structures of human ADAMTS-1 reveal a conserved catalytic domain and a disintegrin-like domain with a fold homologous to cysteine-rich domains. J Mol Biol 2007; 373: 891-902.
52. Mosyak L, Georgiadis K, Shane T, et al. Crystal structures of the two major aggrecan degrading enzymes, ADAMTS4 and ADAMTS5. Protein Sci 2008; 17: 16-21.
53. Durham TB, Klimkowski VJ, Rito CJ, et al. Identification of potent and selective hydantoin inhibitors of aggrecanase-1 and aggrecanase-2 that are efficacious in both chemical and surgical models of osteoarthritis. J Med Chem 2014; 57: 10476-10485.
54. White JM. ADAMs: Modulators of cell-cell and cell-matrix interactions. Curr Opin Cell Biol 2003; 15: 598-606.
55. Bode W, Gomis-Ruth FX, Stockler W. Astacins, serralysins, snake venom and matrix metalloproteinases exhibit identical zinc-binding environments (HEXXHXXGXXH and Met-Turn) and topologies and should be grouped into a common family, the 'metzincins'. FEBS Lett 1993; 331: 134-140.
56. Di Stasio E, Lancellotti S, Peyvandi F, et al. Mechanistic studies on ADAMTS13 catalysis. Biophys J 2008; 95: 2450-2461.
57. Gardner MD, Chion CK, de Groot R, et al. A functional calcium-binding site in the metalloprotease domain of ADAMTS13. Blood 2009; 113: 1149-1157.
58. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87: 4235-4244.
59. Bode W, Fernandez-Catalan C, Tschesche H, et al. Structural properties of matrix metalloproteinases. Cell Mol Life Sci 1999; 55: 639-652.
60. Ai J, Smith P, Wang S, et al. The proximal carboxyl-Terminal domains of ADAMTS13 determine substrate specificity and are all required for cleavage of von Willebrand factor. J Biol Chem 2005; 280: 29428-29434.
61. Gao W, Anderson PJ, Majerus EM, et al. Exosite interactions contribute to tension-induced cleavage of von Willebrand factor by the antithrombotic ADAMTS13 metalloprotease. Proc Natl Acad Sci U S A 2006; 103: 19099-19104.
62. Gao W, Zhu J, Westfield LA, et al. Rearranging exosites in noncatalytic domains can redirect the substrate specificity of ADAMTS proteases. J Biol Chem 2012; 287: 26944-26952.
63. de Groot R, Lane DA, Crawley JT. The ADAMTS13 metalloprotease domain: Roles of subsites in enzyme activity and specificity. Blood 2010; 116: 3064-3072.
64. Xiang Y, de Groot R, Crawley JT, et al. Mechanism of von Willebrand factor scissile bond cleavage by a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13). Proc Natl Acad Sci U S A 2011; 108: 11602-11607.
65. Apte SS. A disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motifs: The ADAMTS family. Int J Biochem Cell Biol 2004; 36: 981-985.
66. Gao W, Anderson PJ, Sadler JE. Extensive contacts between ADAMTS13 exosites and von Willebrand factor domain A2 contribute to substrate specificity. Blood 2008; 112: 1713-1719.
67. de Groot R, Bardhan A, Ramroop N, et al. Essential role of the disintegrin-like domain in ADAMTS13 function. Blood 2009; 113: 5609-5616.
68. Akiyama M, Takeda S, Kokame K, et al. Crystal structures of the noncatalytic domains of ADAMTS13 reveal multiple discontinuous exosites for von Willebrand factor. Proc Natl Acad Sci U S A 2009; 106: 19274-19279.
69. Akiyama M, Nakayama D, Takeda S, et al. Crystal structure and enzymatic activity of an ADAMTS-13 mutant with the East Asian-specific P475S polymorphism. J Thromb Haemost 2013; 11: 1399-1406.
70. Takeda S. Three-dimensional domain architecture of the ADAM family proteinases. Semin Cell Dev Biol 2009; 20: 146-152.
71. Takeda S, Igarashi T, Mori H, et al. Crystal structures of VAP1 reveal ADAMs' MDC domain architecture and its unique C-shaped scaffold. EMBO J 2006; 25: 2388-2396.
72. Tan K, Duquette M, Liu JH, et al. Crystal structure of the TSP-1 type 1 repeats: A novel layered fold and its biological implication. J Cell Biol 2002; 159: 373-382.
73. de Groot R, Lane DA, Crawley JT. The role of the ADAMTS13 cysteinerich domain in VWF binding and proteolysis. Blood 2015; 125: 1968-1975.
74. Wu JJ, Fujikawa K, McMullen BA, et al. Characterization of a core binding site for ADAMTS-13 in the A2 domain of von Willebrand factor. Proc Natl Acad Sci U S A 2006; 103: 18470-18474.
75. Pos W, Crawley JT, Fijnheer R, et al. An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF. Blood 2010; 115: 1640-1649.
76. Jin SY, Skipwith CG, Zheng XL. Amino acid residues Arg (659), Arg (660), and Tyr (661) in the spacer domain of ADAMTS13 are critical for cleavage of von Willebrand factor. Blood 2010; 115: 2300-2310.
77. Davis AK, Makar RS, Stowell CP, et al. ADAMTS13 binds to CD36: A potential mechanism for platelet and endothelial localization of ADAMTS13. Transfusion 2009; 49: 206-213.
78. Bork P, Beckmann G. The CUB domain. A widespread module in developmentally regulated proteins. J Mol Biol 1993; 231: 539-545.
79. Feys HB, Anderson PJ, Vanhoorelbeke K, et al. Multistep binding of ADAMTS-13 to von Willebrand factor. J Thromb Haemost 2009; 7: 2088-2095.
80. Zanardelli S, Chion AC, Groot E, et al. A novel binding site for ADAMTS13 constitutively exposed on the surface of globular VWF. Blood 2009; 114: 2819-2828.
81. Zhang P, Pan W, Rux AH, et al. The cooperative activity between the carboxylterminal TSP1 repeats and the CUB domains of ADAMTS13 is crucial for recognition of von Willebrand factor under flow. Blood 2007; 110: 1887-1894.
82. Tao Z, Peng Y, Nolasco L, et al. Recombinant CUB-1 domain polypeptide inhibits the cleavage of ULVWF strings by ADAMTS13 under flow conditions. Blood 2005; 106: 4139-4145.
83. South K, Luken BM, Crawley JT, et al. Conformational activation of ADAMTS13. Proc Natl Acad Sci U S A 2014; 111: 18578-18583.
84. Muia J, Zhu J, Gupta G, et al. Allosteric activation of ADAMTS13 by von Willebrand factor. Proc Natl Acad Sci U S A 2014; 111: 18584-18589.
85. Yeh HC, Zhou Z, Choi H, et al. Disulfide bond reduction of von Willebrand factor by ADAMTS-13. J Thromb Haemost 2010; 8: 2778-2788.
86. Bao J, Xiao J, Mao Y, et al. Carboxyl terminus of ADAMTS13 directly inhibits platelet aggregation and ultra large von Willebrand factor string formation under flow in a free-Thiol-dependent manner. Arterioscler Thromb Vasc Biol 2014; 34: 397-407.
87. Banno F, Chauhan AK, Kokame K, et al. The distal carboxyl-Terminal domains of ADAMTS13 are required for regulation of in vivo thrombus formation. Blood 2009; 113: 5323-5329.
88. Scheiflinger F, Knobl P, Trattner B, et al. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood 2003; 102: 3241-3243.
89. Grillberger R, Casina VC, Turecek PL, et al. Anti-ADAMTS13 IgG autoantibodies present in healthy individuals share linear epitopes with those in patients with thrombotic thrombocytopenic purpura. Haematologica 2014; 99: E58-e60.
90. Pos W, Sorvillo N, Fijnheer R, et al. Residues Arg568 and Phe592 contribute to an antigenic surface for anti-ADAMTS13 antibodies in the spacer domain. Haematologica 2011; 96: 1670-1677.
91. Igari A, Nakagawa T, Moriki T, et al. Identification of epitopes on ADAMTS13 recognized by a panel of monoclonal antibodies with functional or nonfunctional effects on catalytic activity. Thromb Res 2012; 130: E79-e83.
92. Yamaguchi Y, Moriki T, Igari A, et al. Epitope analysis of autoantibodies to ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. Thromb Res 2011; 128: 169-173.
93. Klaus C, Plaimauer B, Studt JD, et al. Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood 2004; 103: 4514-4519.
94. Luken BM, Turenhout EA, Kaijen PH, et al. Amino acid regions 572-579 and 657-666 of the spacer domain of ADAMTS13 provide a common antigenic core required for binding of antibodies in patients with acquired TTP. Thromb Haemost 2006; 96: 295-301.
95. Pos W, Luken BM, Sorvillo N, et al. Humoral immune response to ADAMTS13 in acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2011; 9: 1285-1291.
96. Schaller M, Vogel M, Kentouche K, et al. The splenic autoimmune response to ADAMTS13 in thrombotic thrombocytopenic purpura contains recurrent antigen-binding CDR3 motifs. Blood 2014; 124: 3469-3479.
97. Luken BM, Kaijen PH, Turenhout EA, et al. Multiple B-cell clones producing antibodies directed to the spacer and disintegrin/thrombospondin type-1 repeat 1 (TSP1) of ADAMTS13 in a patient with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2006; 4: 2355-2364.
98. Jian C, Xiao J, Gong L, et al. Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. Blood 2012; 119: 3836-3843.